Phase 1Not yet recruitingAge-related condition

Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS (ROAR HMB)

A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

Sponsor
Duke University (Academic or other)
Enrollment
100 planned
Conditions
Amyotrophic Lateral Sclerosis ALS
Interventions
β-hydroxy-β-methylbutyrate (HMB)
Ages
adults, older adults
Registry
NCT07589764

Full record on ClinicalTrials.gov

From the registry

This is an open label trial of a supplement called HMB in patients with ALS. The researchers are evaluating its safety and tolerability, as well as its ability to lower insulin-like growth-factor binding protein 7 (IGFBP7) and Neurofilament light chain levels (NFL) and to slow ALS Functional Rating Scale, Revised (ALSFRS-R) progression.

Primary outcomes

  • ALS Functional Rating Scale, Revised (ALSFRS-R)
  • Speech (Listener Effort)

History

  1. Primary completion expected

  2. Expected to start

  3. Last registry update

  4. Registered